MeiraGTx to Host Parkinson’s Disease R&D Day in New York
December 05, 2019
LONDON and NEW YORK,
The day will consist of speaker presentations, a moderated panel, and an audience Q&A session. MeiraGTx’s president and CEO,
Featured guests for the event include:
Ali Rezai, M.D., Executive Chair, Rockefeller Neuroscience Institute; Vice President of Neuroscience; and Professor of Neuroscience, West Virginia University School of Medicine Jamie Eberling, Ph.D., Director, Research Programs, Michael J. Fox Foundationfor Parkinson’s Research Jalpa A. Doshi, Ph.D., Director, Economic Evaluations Unit, Center for Evidence-based Practice; Director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics; and Professor of Medicine, University of Pennsylvania Michael Kaplitt, M.D., Ph.D., Vice Chair, Research, Neurological Surgery and Professor of Neurological Surgery, Weill Cornell Medical College
A live webcast will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. A replay of the webcast will be available for approximately 90 days following the presentation.
AAV-GAD is an investigational gene therapy medicine designed to deliver the GAD gene to the subthalamic nucleus in order to increase production of GABA, the primary inhibitory neurotransmitter in the human brain. GAD is the rate-limiting enzyme in the synthesis of GABA. Therefore, the Company believes that increasing subthalamic nucleus GAD expression through gene therapy has the potential to result in normalization of motor circuits and improve motor symptoms in Parkinson’s disease patients without affecting other brain regions that can be responsible for complications associated with existing therapies.
About Parkinson’s Disease
Parkinson’s disease affects nearly one million Americans with 60,000 new cases diagnosed in the
For more information, please visit www.meiragtx.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding product candidate development, growth expectations or efficacy, as well as statements that include the words “expect,” “intend,” “plan,” “believe,” “project,” “forecast,” “estimate,” “may,” “should,” “anticipate” and similar statements of a future or forward-looking nature. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, our incurrence of significant losses; any inability to achieve or maintain profitability, acquire additional capital, identify additional and develop existing product candidates, successfully execute strategic priorities, bring product candidates to market, expansion of our manufacturing facilities and processes, successfully enroll patients in and complete clinical trials, accurately predict growth assumptions, recognize benefits of any orphan drug designations, retain key personnel or attract qualified employees, or incur expected levels of operating expenses; failure of early data to predict eventual outcomes; failure to obtain